



MICROBA™

Sonic Healthcare Strategic Investment & Commercial Partnership

Investor Briefing

November 2022 | *Authorised for release by the CEO & Chairman*

Disclaimer

This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**).

Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs. This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.

Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Financial data – All dollar values in Australian dollars (A\$ or \$) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

“Advancing microbiome therapeutics and testing into the hands of clinicians and patients, globally”

MICROBA™



SONIC
HEALTHCARE

A globally respected leader





Sonic Healthcare is one of the world's largest medical diagnostics companies

\$16B market cap
- second largest healthcare company on ASX

Generated **revenue of \$9.3B** in FY22

Employs more than **41,000** people globally

Countries of operation
(Years shown are the years Sonic entered each market)



Sonic Strategic Investment & Commercial Partnership

Sonic is investing \$17.8m into Microba to acquire a 19.99% stake

Shares to be acquired at \$0.26. A 25% premium to 5 day VWAP

Post transaction pro-forma, **cash balance increase to \$43.8m***

Sonic will secure rights for microbiome testing distribution in 7 major countries

Strategic distribution into **7 major countries** including UK, Germany and Australia

Global network of **primary and specialist healthcare** professionals

Seeking a further 5% stake via options

Options are subject to shareholder approval at EGM. **Exercise price of \$0.33.** A further significant premium

If options are exercised it could take **Sonic stake to 25%**

Sonic Strategic Partnership – Executing on strategy



Leading bench of healthcare and pathology partners set to deliver Microba's testing into major healthcare markets globally



\$9.3bn Revenue
Partnership: UK, Germany, Belgium, Australia, US, NZ & Switzerland



\$5.8bn Revenue
Partnership: Europe & LATAM




Leading GI Diagnostics in US
Partnership: US



Raised USD \$800m
Partnership: GCC Region

Microba's **Healthcare & Pathology Partners**

Significant international distribution expansion for Microba's testing services




Access into **35 countries**

Operations **only activated in 5 of 35 countries**

Significant growth prospects ahead

Accelerating expansion and adoption



Leading bench of healthcare partners provides access into 35 countries

Staged rollout to be executed to ensure market success

New regions to operationalise in FY23 are in focus

Sonic expected to impact revenue from FY24

“Our partnership with Microba exemplifies our commitment to invest in cutting edge developments in laboratory medicine. We see microbiome testing becoming a key part of pathology over coming years and are excited about the potential of this partnership and the opportunities that Microba's technology will provide for Sonic’s global operations, our referring clinicians and our patients.”


Dr Colin Goldschmidt – CEO Sonic Healthcare



Sonic partnership set to drive Microba's testing deeper into primary and specialist care



145 million patients, globally



New strategic shareholder – Providing strength



Sonic strategic stake aligns both companies and accelerates Microba's therapeutics and testing

**19.99%
equity stake**

- **Ordinary shares**
- **Priced at 26c** - a **25% premium** to the 5 day VWAP
- Raising **\$17.8m in new capital** for the company



**5% stake
through
options**


- **Options**
- Exercise **price of 33c** - a **58% premium** to the 5 day VWAP
- Raising **\$7.5m in additional new capital** for the company
- **Subject to shareholder approval**



**Microba to significantly
advance its microbiome
therapeutics and testing
into the hands of clinicians
and patients, globally**



New funding further accelerates Microba's therapeutics and testing into routine healthcare



Microba's platform for growth

Global testing business with leading partners

- Microba has an excellent platform for continued growth.
- The leadership provided by our partners will guide Microba to a dominant market position



"This partnership is a positive development and another major validation point for Microba"
Ian Frazer, Deputy Chair

Compelling therapeutic programs

- The Microba therapeutics business is on track to move into clinical phase towards out-licensing transactions
- The microbiome therapeutic market is hitting key inflection points with the sector expected to achieve first FDA approvals



"The Microba investment thesis continues to develop to plan, with excellent progress across our two core business segments of testing and therapeutics"
Luke Reid, CEO

Robust financial position

- \$43.8m cash at bank providing balance sheet strength in volatile equity markets*
- Enables continued investment in promising therapeutic activities and global expansion of testing business



"In addition to being an excellent strategic partner, the Sonic partnership enables continued investment in key programs which are expected to yield excellent returns in the medium term"
Pasquale Rombola, Chair

“Sonic is globally respected for its leadership in delivering trusted medical diagnostic services, and our partnership deeply aligns the interests of both companies to bring microbiome testing and therapeutics into the hands of clinicians and patients globally to improve standard of care”

Dr Luke Reid – CEO Microba



Contact



Dr Luke Reid

Chief Executive Officer
luke.reid@microba.com



Pasquale Rombola

Chairman
pasquale.rombola@microba.com

Head Office

Level 10, 324 Queen Street
Brisbane QLD Australia

Laboratory

Princess Alexandra Hospital
Woolloongabba QLD Australia